Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522600 | 0.93 | LMNA (0.53) | LMNAHTTHDAC1CYP2C9SMN1; SMN2 | |
| SCHEMBL2264435 | 0.91 | ALDH1A1 (0.61) | LMNAHTTHDAC1SMN1; SMN2MAPT | |
| SCHEMBL25753418 | 0.91 | LMNA (0.51) | LMNAHTTHDAC1CYP2C9SMN1; SMN2 | |
| SCHEMBL13762029 | 0.91 | HDAC1 (0.67) | LMNAHTTHDAC1SMN1; SMN2MAPT | |
| SCHEMBL162828 | 0.91 | TSHR (0.54) | LMNAHTTCYP2C9SMN1; SMN2MAPT | |
| SCHEMBL13701770 | 0.91 | HDAC2 (0.59) | LMNAHTTSMN1; SMN2EPHX1MAPT | |
| SCHEMBL3716265 | 0.91 | SRD5A2 (0.53) | LMNAHTTCYP2C9SMN1; SMN2EPHX1 | |
| SCHEMBL691761 | 0.89 | KMT2A (0.56) | LMNAHTTHDAC1CYP2C9POLB | |
| SCHEMBL1176575 | 0.89 | LMNA (0.50) | LMNAHTTHDAC1CYP2C9SMN1; SMN2 | |
| SCHEMBL21016381 | 0.89 | EPHX2 (0.51) | LMNAHTTCYP2C9SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12019371-B2 | Photosensitive composition, film, color filter, solid-state imaging element, and image display device | FUJIFILM CORPORATION (JP) | 2024-06-25 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | ARDELYX, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230273354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3475085-B1 | MULTILAYER FILMS AND PACKAGES FORMED FROM SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-109195795-B | Multilayer film and package formed therefrom | 陶氏环球技术有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210223436-A1 | STRUCTURAL BODY, SOLID-STATE IMAGING ELEMENT, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2021-07-22 | — | — | US | disclosed |
| US-20210186953-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20180022894-A1 | POLYETHYLENE COMPOSITIONS WITH IMPROVED OPTICAL PROPERTIES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-01-25 | — | — | US | disclosed |
| US-20170368004-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3260295-A1 | MULTILAYER FILMS AND PACKAGES FORMED FROM SAME | Dow Global Technologies LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-3237521-A1 | POLYETHYLENE COMPOSITIONS WITH IMPROVED OPTICAL PROPERTIES | Dow Global Technologies LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2017-07-27 | — | — | US | disclosed |
| WO-2016105610-A1 | POLYETHYLENE COMPOSITIONS WITH IMPROVED OPTICAL PROPERTIES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-3037466-A1 | Polyethylene compositions with improved optical properties | Dow Global Technologies LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160067242-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20150336892-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | LMNA 1098/4885HTT 4337/4885HDAC1 1081/4885 |
| US-20160067242-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | LMNA 4327/4885HTT 2581/4885HDAC1 1957/4885 |
| US-20150336892-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | LMNA 3770/4885HTT 1823/4885HDAC1 1556/4885 |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | HSD11B2, HSD11B1, HSD3B2 | LMNA 2542/4885HTT 4071/4885HDAC1 1171/4885 |
| US-20180022894-A1 | POLYETHYLENE COMPOSITIONS WITH IMPROVED OPTICAL PROPERTIES | PARG, PARN, FHIT | LMNA 235/4885HTT 232/4885HDAC1 1977/4885 |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | NHERF1, SLC9A3, SLC26A3 | LMNA 3991/4885HTT 2014/4885HDAC1 273/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | LMNA 3836/4885HTT 2060/4885HDAC1 2068/4885 |
| US-20230273354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | GRHPR, REN, GRK5 | LMNA 2166/4885HTT 3334/4885HDAC1 2898/4885 |
| US-20170368004-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | LMNA 3770/4885HTT 1823/4885HDAC1 1556/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | LMNA 3455/4885HTT 4344/4885HDAC1 1016/4885 |
| US-20210186953-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | LMNA 4327/4885HTT 2581/4885HDAC1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.